5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - Results from the COU-AA-301 phase 3 study
    Meeting Abstract

    Harland, S.; de Bono, J. S.; Haqq, C. M.; Staffurth, J. N.; Hao, Y.; Gagnon, D.; Liu, C.; Sternberg, C. N.; Molina, A.; Scher, H. I.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel
    Meeting Abstract

    Fizazi, K.; Scher, H. I.; Molina, A.; Logothetis, C. J.; Jones, R. J.; Staffurth, J. N.; Li, J.; Kheoh, T.; Haqq, C. M.; de Bono, J. S.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial)
    Meeting Abstract

    Escudier, B.; Loomis, A. K.; Kaprin, A.; Motzer, R.; Tomczak, P.; Tarazi, J.; Kim, S.; Gao, F.; Williams, J. A.; Rini, B.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Donskov, F.; Carus, A.; Barrios, C. H.; Escudier, B.; Li, S.; Perkins, J.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma
    Meeting Abstract

    Davis, M. P.; Figlin, R. A.; Hutson, T. E.; Goldstein, D.; Li, S.; Perkins, J.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Comparison of health-related quality of life (HRQoL) in patients reporting the same adverse event (AE) fatigue on different treatments
    Meeting Abstract

    Cella, D.; Bushmakin, A. G.; Cappelleri, J. C.; Charbonneau, C.; Sandin, R.; Negriers, S.; Figlin, R. A.; Michaelson, M. D.; Davis, M. P.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXis trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Cella, D.; Escudier, B.; Rini, B.; Chen, C.; Bhattacharyya, H.; Tarazi, J.; Rosbrook, B.; Kim, S.; Motzer, R.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Visualization of the interstitial cells of Cajal (ICC) network in mice
    Journal Article

    Chen, Y.; Shamu, T.; Chen, H.; Besmer, P.; Sawyers, C. L.; Chi, P.
    Journal of Visualized Experiments (2011)

    Fulltext@MSK | Save
  • The "sWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
    Journal Article

    Nissan, M. H.; Solit, D. B.
    Current Oncology Reports (2011)

    Fulltext@MSK | Save
  • Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib - Response
    Journal Article

    Rini, B. I.; Cohen, D. P.; Lu, D. R.; Chen, I.; Hariharan, S.; Gore, M. E.; Figlin, R. A.; Baum, M. S.; Motzer, R. J.
    JNCI: Journal of the National Cancer Institute (2011)

    Fulltext@MSK | Save